ALGS - Aligos Therapeutics Inc.

-

$undefined

N/A

(N/A)

Aligos Therapeutics Inc. NASDAQ:ALGS Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

Location: | Website: www.aligos.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-34.39M

Cash

94.54M

Avg Qtr Burn

-21.31M

Short % of Float

1.46%

Insider Ownership

20.07%

Institutional Own.

65.62%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Initiation

ALG-055009 (THR-β Agonist) Details
Non-alcoholic steatohepatitis

Phase 2a

Update

Phase 1

Data readout

Failed

Discontinued

ALG-125755 Details
Chronic hepatitis B, Liver disease

Failed

Discontinued